Insider Transactions in Q1 2023 at Cytom X Therapeutics, Inc. (CTMX)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2023
|
Elaine V Jones |
BUY
Open market or private purchase
|
Direct |
5,000
+49.3%
|
$5,000
$1.55 P/Share
|
|
Mar 22
2023
|
Marcia Belvin SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+29.88%
|
-
|
|
Mar 16
2023
|
Amy C. Peterson EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,257
-6.79%
|
$4,257
$1.98 P/Share
|
|
Mar 16
2023
|
Jeffrey B Landau Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,477
-2.09%
|
$1,477
$1.98 P/Share
|
|
Mar 16
2023
|
Lloyd A Rowland General Counsel |
SELL
Open market or private sale
|
Direct |
2,037
-2.79%
|
$2,037
$1.98 P/Share
|
|
Mar 16
2023
|
Sean A. Mc Carthy CEO |
SELL
Open market or private sale
|
Direct |
7,121
-1.8%
|
$7,121
$1.88 P/Share
|
|
Mar 16
2023
|
Carlos Campoy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,748
-4.37%
|
$1,748
$1.98 P/Share
|
|
Mar 16
2023
|
Christopher Ogden Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
516
-1.35%
|
$516
$1.98 P/Share
|
|
Feb 02
2023
|
Sean A. Mc Carthy CEO |
BUY
Grant, award, or other acquisition
|
Direct |
105,000
+20.96%
|
-
|
|
Feb 02
2023
|
Christopher Ogden Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+39.5%
|
-
|
|
Feb 02
2023
|
Lloyd A Rowland General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+25.48%
|
-
|
|
Feb 02
2023
|
Jeffrey B Landau Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+36.13%
|
-
|